Literature DB >> 18638295

Relative potency of ketamine and S(+)-ketamine in dogs.

J C Duque1, N Oleskovicz, E C B P Guirro, C A A Valadão, V E Soares.   

Abstract

The aim of this study was to determine the relative potency of racemic ketamine and S(+)-ketamine for the hypnotic effect and to evaluate the clinical anesthesia produced by equianesthetic doses of these two substances in dogs. One hundred and eight dogs were allocated in groups R2, R2.5, R3, R6, R9, R12, S2, S2.5, S3, S6, S9, and S12, to receive by intravenous route 2, 2.5, 3, 6, 9, and 12 mg/kg of ketamine or S(+)-ketamine, respectively. A dose-effect curve was drawn with the dose logarithm and the percentage of dogs that presented hypnosis in each group. The curve was used to obtain a linear regression, to determine the effective doses 100 and the potency relationship. In another experimental phase, eight groups of five dogs received 3, 6, 9 and 12 mg/kg of ketamine or S(+)-ketamine to evaluate the periods of latency, hypnosis, and total recovery. The times in which the dogs reached the sternal position, attempted to stand up for the first time, recovered the standing position, and started to walk were also recorded. The hypnotic dose for ketamine was 9.82 +/- 3.02 (6.86-16.5) mg/kg and for S(+)-ketamine was 7.76 +/- 2.17 (5.86-11.5) mg/kg. The time of hypnosis was longer in R3 and the first attempt to stand up occurred early in R6 when compared with S3 and S6 respectively. When R9 (100% of hypnosis with ketamine) and S6 [100% of hypnosis with S(+)-ketamine] were compared (1:1.5 ratio), the time to sternal position (12 +/- 2.5 and 20.2 +/- 5.6 min respectively) and the total recovery time (45 +/- 5.5 and 60.2 +/- 5.2 min respectively) were significantly shorter with S(+)-ketamine. It was concluded that the potency ratio between ketamine and S(+)-ketamine in dogs is smaller than the one reported in other species, and that the dose obtained after a reduction of 50%, as usually performed in humans, would not be enough to obtain equianesthetic effects in dogs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18638295     DOI: 10.1111/j.1365-2885.2008.00965.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  6 in total

1.  Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial.

Authors:  Andrew P Carlson; Mohammad Abbas; Robert L Alunday; Fares Qeadan; C William Shuttleworth
Journal:  J Neurosurg       Date:  2018-05-25       Impact factor: 5.115

2.  Clinical and pharmacokinetic evaluation of S-ketamine for intravenous general anaesthesia in horses undergoing field castration.

Authors:  Daniela Casoni; Claudia Spadavecchia; Beat Wampfler; Wolfgang Thormann; Olivier L Levionnois
Journal:  Acta Vet Scand       Date:  2015-05-03       Impact factor: 1.695

Review 3.  First-line management of canine status epilepticus at home and in hospital-opportunities and limitations of the various administration routes of benzodiazepines.

Authors:  Marios Charalambous; Holger A Volk; Luc Van Ham; Sofie F M Bhatti
Journal:  BMC Vet Res       Date:  2021-03-04       Impact factor: 2.741

4.  Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature.

Authors:  Sarah E Grady; Travis A Marsh; Allison Tenhouse; Kelsey Klein
Journal:  Ment Health Clin       Date:  2018-03-23

Review 5.  To use or not to use: an update on licit and illicit ketamine use.

Authors:  Jih-Heng Li; Balasingam Vicknasingam; Yuet-Wah Cheung; Wang Zhou; Adhi Wibowo Nurhidayat; Don C Des Jarlais; Richard Schottenfeld
Journal:  Subst Abuse Rehabil       Date:  2011-03-16

6.  Comparison of intranasal versus intravenous midazolam for management of status epilepticus in dogs: A multi-center randomized parallel group clinical study.

Authors:  Marios Charalambous; Holger A Volk; Andrea Tipold; Johannes Erath; Enrice Huenerfauth; Antonella Gallucci; Gualtiero Gandini; Daisuke Hasegawa; Theresa Pancotto; John H Rossmeisl; Simon Platt; Luisa De Risio; Joan R Coates; Mihai Musteata; Federica Tirrito; Francesca Cozzi; Laura Porcarelli; Daniele Corlazzoli; Rodolfo Cappello; An Vanhaesebrouck; Bart J G Broeckx; Luc Van Ham; Sofie F M Bhatti
Journal:  J Vet Intern Med       Date:  2019-10-03       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.